Fecal Microbiota Transplantation for Steroid-Refractory Acute GI GVHD

Recruiting Phase 2 Interventional Study
Graft vs Host Disease
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Sex
Any
Trial phase
Phase 2
Study type
Interventional
Purpose
Treatment
Participants needed
35 (estimated)
Sponsor
Chang Gung Memorial Hospital · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective treatment for various hematologic diseases. However, one of the major challenges of allo-HSCT is the occurrence of graft-versus-host disease (GvHD), particularly acute gastrointestinal GvHD (GI-GvHD). GvHD occurs when donor T cells recognize the recipient's tissue as foreign and mount an immune attack against it. Acute …
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: 1. Stage II to IV steroid refractory acute GI-GvHD in allo-HSCT recipients 1. Stage II to IV acute GI-GVHD subjects, having \>1000 mL stool per day, diarrhea \> 5 times/day, or abdominal cramping, bleeding or ileus, AND 2. Resistant to a first-line therapy with corticoste…
Contacts

Hsiao-Wen Kao, M.D.

+886-3-3281200

hsiaowen@cgmh.org.tw

CONTACT

Tung-Lian Lin, M.D.

+886-3-3281200

ldl2605@cgmh.org.tw

CONTACT